LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place February 7 – 11, 2022 in San Diego, California. The presentations will include updated data from the Company’s ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1.
Platform Presentation Details:
| Title: | Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1/2 clinical trial |
| Presenter: | Derralynn A. Hughes |
| Session: | Late-Breaking Science |
| Date and Time: | Friday, February 11, 2022, 8:00 AM PT |
Poster Presentation Details:
| Title: | Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1/2 clinical trial |
| Authors: | Derralynn A. Hughes, Sima Canaan-Kühl, Sharon Barton, Richard Collis, Nicole Sherry |
| Presentation #: | LB-30 |
| Date: | Tuesday, February 8, 2022 |
| Title: | Design of GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 |
| Authors: | Derralynn A. Hughes, Sharon Barton, Nicole Sherry |
| Presentation #: | 127 |
| Date: | Wednesday, February 9, 2022 |
The poster presentations will be available on the Investors section of Freeline’s website following presentation at the WORLDSymposium™ conference.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.